Suppression of prostate cancer growth by resveratol in the transgenic for adenocarcinoma of prostate (TRAP) model

Asian Pacific Journal of Cancer Prevention

Volumn 9, Issue 1, 2008, Pages 7-14

  Seeni, Azman ^a   Takahashi, Satoru ^a   Takeshita, Kentaro ^a   Tang, Mingxi ^a   Sugiura, Satoshi ^a   Sato, Shin Ya ^a   Shirai, Tomoyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Chemoprevention; Prostate cancer; Resveratol; TRAP rats

Indexed keywords

EID: 58349100590     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Asamoto M, Hokaiwado N, Cho YM, et al (2001a). Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res, 61, 4693-700.
2. Asamoto M, Hokaiwado N, Cho YM, et al (2001b). Metastasizing neuroblastomas from taste buds in rats transgenic for the Simian virus 40 large T antigen under control of the probasin gene promoter. Toxicol Pathol, 29, 363-8.
3. Asamoto M, Hokaiwado N, Cho YM, et al (2002). Effects of genetic background on prostate and taste bud carcinogenesis due to SV40 T antigen expression under probasin gene promoter control. Carcinogenesis, 23, 463-7.
4. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al (2004). Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res, 24, 2783-840.
5. Aziz MH, Kumar R, Ahmad N (2003). Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol, 23, 17-28.
6. Baur JA, Sinclair DA (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov, 5, 493-506.
7. Baur JA, Pearson KJ, Price NL, et al (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444, 337-42.
8. Banerjee S, Bueso-Ramos C, Aggarwal BB (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res, 62, 4945-54.
9. Bhat KP, Pezzuto JM (2002). Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci, 957, 210-29.
10. Bove K, Lincoln DW, Tsan MF (2002). Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun, 291, 1001-5.
11. Cho YM, Takahashi S, Asamoto M, et al (2003). Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: lack of influence of carcinogen or testosterone treatment. Cancer Sci, 94, 153-7.
12. Chun JY, Nadiminty N, Lee SO, et al (2006). Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Mol Cancer Ther, 5, 913-8.
13. Delmas D, Lancon A, Colin D, et al (2006). Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets, 7, 423-42.
14. Friel H, Lederman H (2006). A nutritional supplement formula for influenza A (H5NCancer Epidemiol Biomarkers Prev, 16, 2193-2203.Cancer Epidemiol Biomarkers Prev, 16, 2193-2203) infection in humans. Med Hypotheses, 67, 578-87.
15. Gescher AJ, Steward WP (2003). Relationship between mechanisms,bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev, 12, 953-7.
16. Hsieh TC, Wu JM (2000). Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res, 20, 225-8.
17. Jang M, Cai L, Udeani GO, et al (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-20.
18. Jemal A, Siegel R, Ward E, et al (2007). Cancer statistics. CA Cancer J Clin, 57, 43-66.
19. Jones SB, DePrimo SE, Whitfield ML, et al (2005). Resveratrolinduced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev, 14, 596-604.
20. Juan ME, Vinardell MP, Planas JM (2002). The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr, 132, 257-60.
21. Kandori H, Suzuki S, Asamoto M, et al (2005). Influence of atrazine administration and reduction of calorie intake on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats. Cancer Sci, 96, 221-6.
22. Kato K, Takahashi S, Mori T et al (1998). Establishment of transplantable rat prostate carcinomas from primary lesions induced by 3,2′-dimethyl-4-aminobiphenyl and testosterone. J Toxicol Pathol, 11, 27-32.
23. Kyprianou N, Isaacs JT (1988). Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology, 122, 552-62.
24. Lagouge M, Argmann C, Gerhart-Hines Z, et al (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 127, 1109-22.
25. Mitchell SH, Zhu W, Young CY (1999). Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res, 59, 5892-5.
26. Nakanishi H, Takeuchi S, Kato K, et al (1996). Establishment and characterization of three androgen-independent, metastatic carcinoma cell lines from 3,2′-dimethyl-4-aminobiphenyl-induced prostatic tumors in F344 rats. Jpn J Cancer Res, 87, 1218-26.
27. Palamara AT, Nencioni L, Aquilano K, et al (2005). Inhibition of influenza A virus replication by resveratrol. J Infect Dis, 191, 1719-29.
28. Sadi MV, Walsh PC, Barrack ER (1991). Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer, 67, 3057-64.
29. Said MM, Hokaiwado N, Tang M, et al (2006). Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by leuprorelin, a luteinizing hormone-releasing hormone agonist. Cancer Sci, 97, 459-67.
30. Schoonen WM, Salinas CA, Kiemeney LA, et al (2005). Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer, 113, 133-40.
31. Stewart JR, Artime MC, O'Brian CA (2003). Resveratrol: a candidate nutritional substance for prostate cancer prevention. J Nutr, 133, 2440S-3S.
32. Sporn MB, Suh N (2002). Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer, 2, 537-43.
33. Syed DN, Khan N, Afaq F, et al (2007). Chemoprevention of prostate cancer through dietary agents: Progress and promise.
34. Tang M, Ogawa K, Asamoto M, et al (2007). Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. Cancer Sci, 98, 471-7.
35. Tsao AS, Kim ES, Hong WK (2004). Chemoprevention of cancer. CA Cancer J Clin, 54, 150-80.
36. Valenzano DR, Terzibasi E, Genade T, et al (2006). Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol, 16, 296-300.
37. Vitaglione P, Sforza S, Galaverna G, et al (2005). Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res, 49, 495-504.
38. Wexler H (1966). Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst, 36, 641-5.
39. Zeng Y, Yokohira M, Saoo K, et al (2005). Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor. Carcinogenesis, 26, 1109-16.
40. Zhang Y, Ni J, Messing EM, et al (2002). Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci USA, 99, 7408-13.